ADT3: A Potential First-In-Class EGFR X Vδ1 Bispecific Engager for In Situ Activation of Vδ1 Γδ T Cells And Enhanced Cytotoxicity Towards Solid Tumors
Time: 9:30 am
day: Conference Day Two
Details:
- ADT3 is a bispecific engager that is designed to activate tissue resident VD1 T cells
- ADT3 activates VD1 Gamma delta T cells via crosslinking through EGFR on tumor cells resulting in proliferation, activation and tumor cell killing
- Activation of VD1 cells via ADT3 enables activated Vd1 cells to recognize and kill EGFR positive and EGFR negative tumor cells while sparing EGFR positive healthy cells
